443 related articles for article (PubMed ID: 8076383)
1. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer.
Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A
Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383
[TBL] [Abstract][Full Text] [Related]
2. [Usefulness of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), enolase (NSE) and thymidine-kinase (TK) in the monitoring and prognosis of primary carcinoma of the lung].
De Angelis G; De Marinis F; Bigioni D; Migliorino MR; Alma MG; Pigorini F
J Nucl Med Allied Sci; 1990; 34(4 Suppl):135-40. PubMed ID: 1965445
[No Abstract] [Full Text] [Related]
3. Evaluation of the response to chemotherapy in patients affected with small cell lung cancer using discriminant analysis: a preliminary report.
Paone G; De Angelis G; Pallotta G; Giannarelli D; Bisetti A; Pigorini F; Ameglio F
Q J Nucl Med; 1995 Jun; 39(2):140-3. PubMed ID: 8574809
[TBL] [Abstract][Full Text] [Related]
4. [Significance of combined determination of CK19mRNA, carcinoembryanic antigen, neuron-specific enolase, and tissue polypeptide antigen in peripheral blood of patients with lung cancer].
Pan QR; Zhang X; Xu ZF; Zheng S
Ai Zheng; 2002 Feb; 21(2):196-9. PubMed ID: 12479076
[TBL] [Abstract][Full Text] [Related]
5. Five tumor markers in lung cancer: significance of total and "lipid"-bound sialic acid.
Kakari S; Stringou E; Toumbis M; Ferderigos AS; Poulaki E; Chondros K; Dema A; Kotsovoulou V; Pavlidis N
Anticancer Res; 1991; 11(6):2107-10. PubMed ID: 1663720
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Cyfra 21-1 as a marker for lung cancer.
Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R
Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188
[TBL] [Abstract][Full Text] [Related]
7. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer.
Schneider J; Philipp M; Salewski L; Velcovsky HG
Clin Lab; 2003; 49(1-2):35-42. PubMed ID: 12593474
[TBL] [Abstract][Full Text] [Related]
8. Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases.
Schneider J; Philipp M; Velcovsky HG; Morr H; Katz N
Anticancer Res; 2003; 23(2A):885-93. PubMed ID: 12820318
[TBL] [Abstract][Full Text] [Related]
9. ProGRP and NSE in therapy monitoring in patients with small cell lung cancer.
Wójcik E; Kulpa JK; Sas-Korczyńska B; Korzeniowski S; Jakubowicz J
Anticancer Res; 2008; 28(5B):3027-33. PubMed ID: 19031951
[TBL] [Abstract][Full Text] [Related]
10. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
[TBL] [Abstract][Full Text] [Related]
11. [Value of combined detection of tumor markers for the prediction of small cell and non-small cell lung cancer].
Wu Y; Wu Y; Wang L; Qu L
Wei Sheng Yan Jiu; 2000 Jul; 29(4):213-5. PubMed ID: 12520921
[TBL] [Abstract][Full Text] [Related]
12. Clinical value of neuron specific enolase and tissue polipeptidic antigen for the management of patients with lung cancer.
Spinazzi A; Soresi E; Borghini U; Boffi R; Vigorelli R; Scoccia S
J Nucl Med Allied Sci; 1990; 34(4 Suppl):141-5. PubMed ID: 1965446
[No Abstract] [Full Text] [Related]
13. [Determination of various tumor markers, with special reference to neuron-specific enolase in lung cancer].
Yano H; Hino M; Nishiwaki Y; Kodama T; Hayashibe A; Kudo H; Inoue Y; Nishiyama Y; Sone Y; Oshima T
Gan To Kagaku Ryoho; 1987 Jan; 14(1):77-83. PubMed ID: 3026257
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of monitoring levels of carcinoembryonic antigen, neuron-specific enolase and ferritin in serum of patients with small cell lung cancer for evaluating treatment outcome].
Szturmowicz M; Rogińska E; Roszkowski K; Kwiek S; Filipecki S; Rowińska-Zakrzewska E
Pneumonol Alergol Pol; 1993; 61(9-10):489-95. PubMed ID: 8111325
[TBL] [Abstract][Full Text] [Related]
15. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
16. [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer].
Fukuoka M; Takada M; Kamei T; Negoro S; Kusunoki Y; Matsui K; Ryu S; Sakai N; Takifuji N; Masuda N
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):871-80. PubMed ID: 3032108
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of therapy in inoperable lung cancer patients by measurement of CYFRA 21-1, TPA- TP CEA, and NSE.
Ebert W; Hoppe M; Muley T; Drings P
Anticancer Res; 1997; 17(4B):2875-8. PubMed ID: 9329552
[TBL] [Abstract][Full Text] [Related]
18. Serum pseudouridine as a biochemical marker in small cell lung cancer.
Tamura S; Fujioka H; Nakano T; Hada T; Higashino K
Cancer Res; 1987 Nov; 47(22):6138-41. PubMed ID: 2822241
[TBL] [Abstract][Full Text] [Related]
19. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
20. Significance of neuron-specific enolase levels before and during therapy for small cell lung cancer.
Bonner JA; Sloan JA; Rowland KM; Klee GG; Kugler JW; Mailliard JA; Wiesenfeld M; Krook JE; Maksymiuk AW; Shaw EG; Marks RS; Perez EA
Clin Cancer Res; 2000 Feb; 6(2):597-601. PubMed ID: 10690544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
